LoginSignup
Altimmune logo

Altimmune Stock

StockStock
ISIN: US02155H2004
Ticker: ALT
US02155H2004
ALT

Price

Frequently asked questions

What is Altimmune's market capitalization?

The market capitalization of Altimmune is $674.46M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Altimmune?

Altimmune's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.618. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Altimmune's stock?

Currently, 9 analysts cover Altimmune's stock, with a consensus target price of $20.57. Analyst ratings provide insights into the stock's expected performance.

What is Altimmune's revenue over the trailing twelve months?

Over the trailing twelve months, Altimmune reported a revenue of $409.00K.

What is the EBITDA for Altimmune?

Altimmune's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$96.64M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Altimmune?

Altimmune has a free cash flow of -$71.49M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Altimmune's stock?

The 5-year beta for Altimmune is 0.16. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Altimmune have, and what sector and industry does it belong to?

Altimmune employs approximately 59 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Altimmune's shares?

The free float of Altimmune is 70.51M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $674.46M

5Y beta

 0.16

EPS (TTM)

 -$1.618

Free Float

 70.51M

Revenue (TTM)

 $409.00K

EBITDA (TTM)

 -$96.64M

Free Cashflow (TTM)

 -$71.49M

Pricing

1D span
$9.308$11.06
52W span
$2.343$14.84

Analyst Ratings

The price target is $20.57 and the stock is covered by 9 analysts.

Buy

7

Hold

2

Sell

0

Information

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

59

Biotechnology & Drugs

Health Care

Identifier

ISIN

US02155H2004

Primary Ticker

ALT

Knockouts

Join the conversation
Sign upLogin